Skip to main content
Journal Guides6 min readUpdated Jun 18, 2026

Is JAMA Oncology Indexed in PubMed? Yes, and MEDLINE Is Active

JAMA Oncology is indexed in PubMed and currently indexed for MEDLINE, which matters because broad oncology papers need search visibility across clinical and academic readers.

By Manusights Editorial Team•
Editorial processThe Manusights editorial team researches and maintains our Clinical Medicine & Public Health guides, drawing on what we see across thousands of pre-submission manuscript reviews.How we work

Next step

Choose the next useful decision step first.

Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.

Open Journal Fit ChecklistAnthropic Privacy Partner. Your manuscript is never used to train any model.Run Free Readiness Scan
Journal context

JAMA Oncology at a glance

Key metrics to place the journal before deciding whether it fits your manuscript and career goals.

Full journal profile
Acceptance rate~8%Overall selectivity
Time to decision21 days medianFirst decision

What makes this journal worth targeting

  • JAMA Oncology's scope and readership determine whether the journal is a useful target.
  • Scope specificity matters more than headline metrics for most manuscript decisions.
  • Acceptance rate of ~8% means fit determines most outcomes.

When to look elsewhere

  • When your paper sits at the edge of the journal's stated scope, borderline fit rarely improves after submission.
  • If timeline matters: JAMA Oncology takes 21 days median. A faster-turnaround journal may suit a grant or job deadline better.
  • If open access is required by your funder, verify the journal's OA agreements before submitting.

Quick answer: yes. JAMA Oncology is indexed in PubMed and currently indexed for MEDLINE from volume 1, issue 1 in April 2015. That is the straightforward discoverability answer.

The more useful interpretation is that the title entered the biomedical search system cleanly from launch, which matters for a journal trying to sit between high-end clinical oncology, translational cancer work, outcomes research, and guideline-relevant evidence.

Direct answer

If you publish in JAMA Oncology, your paper is discoverable in PubMed and the title remains actively indexed for MEDLINE.

NLM field
What the record shows
Why it matters
publication start year
2015
the title is newer than legacy oncology flagships
PubMed coverage
v1n1, Apr. 2015-
searchable from launch
MEDLINE coverage
v1n1, Apr. 2015-
curated NLM indexing also starts from launch
current indexing status
Currently indexed for MEDLINE
active indexing is intact
current subset
Index Medicus
standard medical-scientific subset support
NLM profile shape
clean active record
no delayed MEDLINE start or archive ambiguity

That is a strong indexing record for a broad oncology title that needs immediate visibility across subspecialties.

Why this matters for JAMA Oncology

Strong JAMA Oncology papers often want to reach more than one cancer audience at once:

  • practicing oncologists
  • fellows and trainees
  • trialists and translational researchers
  • outcomes and health-services groups
  • systematic reviewers and guideline authors

Those readers often search by cancer type, biomarker, therapy class, endpoint, toxicity, or survivorship issue rather than by browsing a journal issue. PubMed indexing matters because that is how a paper enters the real oncology search workflow after publication.

For a journal positioned as broad oncology rather than a single-disease venue, that search behavior is a large part of its actual influence.

What the indexing record tells you in practice

Practical question
What the record tells you
will a newly published paper show up in PubMed?
yes
is the journal actively indexed for MEDLINE?
yes
did that coverage begin from launch?
yes
is there archive-timeline nuance to decode?
not much
does this prove the manuscript belongs in JAMA Oncology?
no

That final line remains the important one.

PubMed versus MEDLINE for a broad oncology journal

For JAMA Oncology, the distinction is still worth keeping precise:

  • PubMed means the paper is visible in the main biomedical search interface.
  • MEDLINE means the journal is actively inside the curated NLM journal index.

Because the two lines start together from the first issue, the discoverability story is clean. The journal is not in some transition state or partial archive state. If a paper lands here, the database side is already solved.

How this compares with nearby oncology journals

Journal pattern
What the indexing record usually supports
What it does not solve
broad oncology title like JAMA Oncology
wide oncology discoverability from launch
whether the paper has enough cross-disease relevance
flagship general-medicine journal
even broader clinical reach
whether the work is too oncology-specific
narrow disease-area oncology journal
targeted specialty visibility
broader cross-oncology attention

So yes, the indexing record here is strong. It still does not answer whether the paper reads as broad oncology rather than disease-specific incremental work.

How to verify the record yourself

You can verify the record directly in a few steps:

  1. open the NLM Catalog record
  1. confirm the PubMed coverage line
  1. confirm the MEDLINE coverage line
  1. check Current Indexing Status
  1. run a journal-title search in PubMed

For this title, the manual check is simple because the record is unusually clean: PubMed and MEDLINE both begin at launch in April 2015.

What we see in PubMed-indexing questions for JAMA Oncology

For PubMed-indexing questions for JAMA Oncology, three patterns come up repeatedly.

The prestige shortcut. Authors sometimes ask this as if a strong indexing record should answer the submission question. It does not. The NLM record tells you the paper will be visible if accepted. It does not tell you the manuscript is broad enough for the journal.

The oncology-breadth mistake. We often see papers that are solid inside one disease or trial niche but not clearly relevant beyond that lane. JAMA Oncology usually wants work that travels across oncology readership more effectively than a narrower specialty journal paper.

The discoverability underestimate. Some authors treat indexing as almost irrelevant because the brand is already strong. That is sloppy thinking. Oncology papers still need to move through PubMed-driven search behavior, and that is where clinicians, fellows, and review authors actually work.

That is the useful information gain here. The discoverability record is strong. The journal-fit question is still separate.

What the NLM record means in practice for authors

The JAMA Oncology NLM record tells you the title entered the biomedical indexing system cleanly from the start. That means discoverability is not the weak point in your submission strategy.

If a paper is accepted, it will be visible in PubMed and supported by active MEDLINE indexing immediately. That is valuable for oncology because papers need to move quickly across subspecialty tumor boards, guideline work, trial discussions, and evidence reviews.

But the record also tells you what it cannot tell you. It says nothing about whether the manuscript has enough consequence, breadth, or oncology-wide interest for the journal. The hard part of a JAMA Oncology submission is not whether the paper can be found. It is whether it deserves the readership.

What indexing does and does not tell you

This page answers the discoverability question. It does not answer whether your manuscript is broad enough or consequential enough for JAMA Oncology.

Indexing tells you:

  • the paper will be visible in PubMed
  • the journal is actively indexed for MEDLINE
  • the record is clean from launch

Indexing does not tell you:

  • whether the work matters outside one oncology niche
  • whether the study is methodologically strong enough
  • whether a narrower oncology venue would fit better

That is why the more useful next pages are:

If the fit question is what you actually need answered, a JAMA Oncology submission readiness check is the right next step before submission.

Submit If / Think Twice If

Use this indexing answer as enough reassurance if:

  • your concern is basic oncology search visibility
  • you want confirmation of active MEDLINE indexing
  • you need to know whether the title had clean launch-to-index continuity

Think twice if:

  • you are treating indexing as a shortcut for prestige or fit
  • the manuscript may still be too narrow for a broad oncology readership
  • what you really need is an editorial-bar judgment, not a database-status answer

If the fit question is what you actually need answered, a JAMA Oncology submission readiness check gives you a manuscript-specific signal before you submit.

Readiness check

Run the scan while the topic is in front of you.

See score, top issues, and journal-fit signals before you submit.

Get free manuscript previewAnthropic Privacy Partner. Your manuscript is never used to train any model.See example reports

Practical verdict

Yes, JAMA Oncology is indexed in PubMed and currently indexed for MEDLINE, with both lines starting from launch in April 2015.

If your question is whether a published paper will be visible in the main oncology search workflow, the answer is yes. If your real question is whether the manuscript deserves a JAMA Oncology audience rather than a narrower oncology venue, that is a separate editorial-fit call.

Or see example reports before you finalize.

Frequently asked questions

Yes. JAMA Oncology is indexed in PubMed and currently indexed for MEDLINE according to the NLM Catalog.

Yes. The NLM Catalog shows PubMed and MEDLINE coverage from volume 1, issue 1 in April 2015.

Because JAMA Oncology papers are meant to reach oncologists, fellows, trialists, outcomes researchers, and review authors through search-driven oncology workflows.

Open the journal’s NLM Catalog record, check the MEDLINE and PubMed lines plus current indexing status, then confirm recent JAMA Oncology articles appear normally in PubMed.

References

Sources

  1. 1. JAMA Oncology NLM Catalog record, NLM.
  2. 2. NLM Catalog help: current indexing status, NLM.
  3. 3. JAMA Oncology journal page, JAMA Network.
  4. 4. JAMA Oncology instructions for authors, JAMA Network.
  5. 5. JAMA Oncology in PubMed, PubMed.

Before you upload

Choose the next useful decision step first.

Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.

Use the scan once the manuscript and target journal are concrete enough to evaluate.

Anthropic Privacy Partner. Your manuscript is never used to train any model.

Open Journal Fit ChecklistRun Free Readiness Scan
Internal navigation

Where to go next

Start here

Same journal, next question

Supporting reads

Conversion step

Back to all articles